CASI Pharmaceuticals Inc., of Rockville, Md., said a decision was reached to stop further patient enrollment in the phase II open-label study of ENMD-2076 in previously treated locally advanced or metastatic triple-negative breast cancer (TNBC) conducted at the University of Colorado, Denver, and the Indiana University Melvin and Bren Simon Cancer Center.